How To Use CBD Oil To Treat Symptoms of Kidney Infection

What Are the Symptoms of Kidney Infection?

When an infection begins in the urethra or bladder, the first symptoms include frequently feeling like you need to urinate, cloudy urine, or a burning sensation when going to the bathroom. If the infection travels to the kidneys, there are more serious symptoms to look for.

•         Pain in the back, side, groin, or abdomen

•         Chills

•         Fever

•         Pus or blood in the urine

•         Nausea or vomiting

What Causes Kidney Infection?

The most common cause of a kidney infection is E.coli bacteria that travels from the urethra to the kidneys. Not all kidney infections begin at the urethra or bladder, though. Bacterial infections can also travel to your kidneys from other parts of the body.

Some risk factors determine whether you are more prone to suffer from a kidney infection. Women are more likely to suffer due to shorter urethras, for example. Other risk factors include having a weakened immune system, using urinary catheters for long periods of time, or nerve damage around the bladder.

How Do You Treat a Kidney Infection?

If you have symptoms of a kidney infection, it is important to visit your doctor. Left untreated, an infection can lead to serious complications. Some people suffer from chronic kidney infections due to other diseases, such as diabetes. In these situations, sometimes CBD manages symptoms of kidney disease.

Studies show that many patients who suffer chronic kidney disease saw about a 30% reduction in their symptoms. CBD may also slow the progression of kidney disease. The required dosage of CBD for kidney infection depends on your body composition and the advancement of your disease. Trial and error are usually used to find the correct dose.  

While CBD oil can relieve the symptoms of kidney infections, it is not meant to be an alternative to medical treatment. Use CBD oil in conjunction with the treatment recommended by your medical professional. 

The post How To Use CBD Oil To Treat Symptoms of Kidney Infection appeared first on Smart CBD Hub.

from Smart CBD Hub https://smartcbdhub.com/how-to-use-cbd-oil-to-treat-symptoms-of-kidney-infection/
via IFTTT

source https://ozlemhermsen.tumblr.com/post/671929319182024704

CBD for Managing Renal Disease Symptoms

Diabetes and high blood pressure are responsible for most cases of CKD. Age and family history of chronic renal disease can also play a risk factor.

Symptoms of Renal Disease

Signs of CKD include:

•         Chronic pain

•         High blood pressure

•         Anemia

•         Nausea and vomiting

•         Ankle and foot swelling

•         Problems sleeping

Symptoms are often nonspecific, meaning they can also be signs of other diseases. They may not appear until CKD has caused kidney damage.

CBD for Treatment of Chronic Kidney Disease

The symptoms of CKD are often burdensome for patients. Scientists are studying ways to help CKD sufferers manage symptoms and improve their quality of life. Research is taking place on the use of CBD for renal failure treatment.

CBD, or cannabidiol, is a component of marijuana. It does not contain THC, the chemical that produces psychoactive effects. CBD acts on the body’s endocannabinoid system. The role of the endocannabinoid system is to regulate a range of processes in the body, including pain, inflammation, sleep and digestive function.

Research on the use of CBD for pain and inflammation has been promising. These and other symptoms of chronic kidney disease such as nausea and trouble sleeping may be relieved by CBD, which is thought to help the endocannabinoid system regulate these functions.

If you’re considering using CBD oil to treat CKD symptoms, talk to your doctor. He or she can help you determine if CBD is right for you.

The post CBD for Managing Renal Disease Symptoms appeared first on Smart CBD Hub.

from Smart CBD Hub https://smartcbdhub.com/cbd-for-managing-renal-disease-symptoms/
via IFTTT

source https://ozlemhermsen.tumblr.com/post/671295165198172160

Can CBD Help Treat Memory Problems Caused By PTSD?

What Memory Problems Are Associated With PTSD?

Memory problems and associated trouble concentrating are a frequent symptom of PTSD. In many cases, individuals suffering from PTSD may have memory lapses around the specific, traumatizing incident.

The link between post-traumatic stress disorder and memory problems is not entirely clear; however, research suggests, among other things, that predisposition to memory problems may actually be a risk factor for memory problems associated with PTSD.

How Are Memory Problems Associated With PTSD Treated?

In general, PTSD is best treated clinically by a combination of psychotherapy and medication, when it is deemed necessary.

Certain practices can improve memory problems associated with post-traumatic stress disorder. These include getting sufficient sleep, and practicing meditation and/or other mindfulness practices. In many cases, these are employed alongside speaking with a professional, and if necessary using medication.

Can CBD Help Treat Memory Problems Associated With PTSD?

There is evidence that CBD can be a helpful treatment for post-traumatic stress disorder. In particular, evidence suggests that CBD may have benefits associated with memory processing.

Setting this aside, CBD is widely used for anxiety disorders, and evidence suggests that CBD for anxiety can be a useful treatment. There is also some evidence suggesting CBD for better sleep can be a useful treatment — and in particular CBD for insomnia, which along with nightmares is sometimes associated with PTSD. (As noted, better sleep may help improve memory problems associated with PTSD.)

Ultimately, more research is needed to fully understand the link between CBD and PTSD-related memory problems. Individuals experiencing memory issues associated with PTSD should consult with a medical professional about possible dosage of CBD for memory problems.

The post Can CBD Help Treat Memory Problems Caused By PTSD? appeared first on Smart CBD Hub.

from Smart CBD Hub https://smartcbdhub.com/can-cbd-help-treat-memory-problems-caused-by-ptsd/
via IFTTT

source https://ozlemhermsen.tumblr.com/post/670936569630326784

The Year in Review: Pressure Points Against Progress

By New Frontier Data staff

Partisan Pushback against Public Acceptance

Government-led rollbacks of voter-approved initiatives in Mississippi and South Dakota illustrate growing political friction as legalization increasingly extends to conservative markets. More than two-thirds (68%) of Americans surveyed believe that cannabis should be legal. As each new year has been bringing fresh developments in the forms of new markets, novel products, and increasingly diverse experiences, there remains some fundamental disconnects between the court of public opinion and the implementation of policy to align with sentiments for reforms.

The passage of six cannabis-related ballot measures in five states during the 2020 U.S. elections represented the latest momentum for the sector. Arizona, Montana, and New Jersey each approved measures legalizing cannabis for personal use, while Mississippi approved a medical cannabis program. South Dakota, in a unique turn, approved separate ballot measures supporting each medical and adult use of cannabis.

However, in the year since the ballot mandates, procedural objections and technicalities have been raised to impede or overturn the voter-approved initiatives.

In South Dakota, the recreational cannabis ballot initiative — Amendment A — was invalidated on procedural grounds. A lawsuit funded by the administration of Gov. Kristi Noem ® argued that the provisions of Amendment A violated the state’s single subject requirement for ballot initiatives. The South Dakota Supreme Court ultimately agreed, striking down the law and dealing a blow to advocates of the narrowly won measure.

Noem, who dismissed the voters’ “wrong choice” after the measure passed, hailed the court’s ruling. However, the victory on a technicality may be short-lived, as cannabis advocates have successfully demonstrated the majority support among the electorate, which trends indicate will only increase over time.

There have been other instances in 2021 of procedural objections utilized to undermine successful cannabis ballot initiatives. Despite nearly 69% of voters’ approval of medical marijuana, the Mississippi Supreme Court overturned Initiative 65 in response to a challenge of the initiative’s validity based on a failure to meet the required number of signatures required to qualify for the ballot. There too, conservative opponents used a technically to forestall the passage of a decidedly popular measure.

Bowing to public pressure, Mississippi lawmakers proposed legislation to create a medical marijuana program mirroring that approved by voters in November, though plans to convene a special session to vote on the measure have stalled.

The tension between rising public approval versus long-entrenched opposition among conservative lawmakers, looks to be a recurring theme in the coming years as public attitudes evolve more broadly than partisan opposition against the issue. South Dakota and Mississippi illustrate some legislative and legal maneuvers that can impede or overturn voter approved measures. However, as more adults embrace new levels of acceptance for cannabis in American society, opponents will conversely face challenges to maintain a prohibitionist status quo.

Political Posturing, But No Federal Progress

With the passage of several state-level ballot measures in 2020 and Democrats taking control of Congress and the White House, expectations were high that 2021 would be the year for historic federal reform. Both Joe Biden and Kamala Harris had expressed support, if mildly, for reforms around cannabis laws, social equity, and criminal justice. Senate Majority leader Chuck Schumer (D-NY) began the new year touting a historic piece of legislation to deschedule and regulate cannabis in the U.S., and by July released a discussion draft of the Cannabis Administration and Opportunity Act, a sweeping piece of legislation that would not only decriminalize cannabis, but establish a range of programs for cannabis research, social equity, expungement of cannabis convictions, and to delegate regulatory powers from the DEA. At year’s end, however, the CAOA has not been formally introduced in Congress, and there seems to be little consensus on the bill’s provisions.

In November, Rep. Nancy Mace (R-S.C.) introduced an alternative piece of cannabis legislation, the States Reform Act, to similarly decriminalize cannabis and establish a framework for regulating and taxing the industry while providing for the expungement of records for nonviolent cannabis offenders. There, too, the year ended without movement. Unsurprisingly, given the inaction on Capitol Hill, there was likewise little progress made on efforts to reform cannabis banking, as an attempt to wrap the SAFE Banking Act into an essential defense spending bill also failed.

Given the evanescent enthusiasm for federal action in 2021 which failed to see results, the practical outlook for progress from the federal level in 2022 is much less hopeful.

Gaining a Sporting Chance

U.S. sprinter Sha’Carri Richardson’s high-profile cannabis-related disqualification after the U.S. Olympic trials demonstrated that Americans have become significantly more tolerant of cannabis use, even if some dramatically inaccurate stereotypes persist.

Richardson, a favorite for world gold in the 100-meter sprint, had her qualifying run invalidated, and she was subjected to a one-month suspension after testing positive for THC metabolites —the suspension being just long enough to prevent her from running in the Olympic 100-meter event 29 days later.

Many Americans expressed frustration at the outcome, noting that her consumption occurred in an adult-use state, and thus was wholly legal. Many also expressed compassion and understanding for her using it under the stress of her mother’s death.

Despite overwhelmingly supportive sentiments being expressed, the story also revealed some pervasive, broadly inaccurate stereotypes about cannabis users. While speaking/tweeting/posting in support of Sha’Carri Richardson, many commented about her achievement being even more impressive within the context that she was a cannabis consumer, a notion playing on the stereotype of a lazy, slow, apathetically unproductive stoner.

Regardless, Richardson represented the latest world-class athlete to acknowledge personal cannabis use; with wider social acceptance, most professional leagues ending their testing for cannabis, and more professional endorsements being made by retired sports figures, many more athletes are expected to follow her lead in the year ahead.

How Will the Hemp Harvest Grow?

While the decline of U.S. hemp production acreage in 2021 may be construed to mean that hopes for a domestic hemp industry has fizzled, looking only at overall acreage does not capture the fluctuations in different production and market categories. In the past three years, it has been estimated that 80%-90% of acreage planted in the U.S. had been singularly dedicated to CBD production. New Frontier Data estimates that in 2021, there were 40,000 acres planted, though only 23,000 acres (58%) harvested, due to losses through drought and crop failure.

The 2021 decline of hemp acreage was indicative of the industry’s effort to balance supply with still nascent market demand. The hemp sector continues to struggle to find equilibrium between supply and demand due to the opacity of the industry and a lack of centralized data to inform production and pricing decisions.

Nevertheless, while CBD acreage has diminished year-over-year, grain and fiber acreage has steadily increased. The past summer served as a pilot year for producers to dial in the agronomics of successfully growing a hemp crop for grain and/or fiber. New Frontier Data estimates that in 2022 and beyond, acreage will increase as large-scale, contract production will be necessary to feed the processing capacity of grain and fiber processors that have come online around the U.S. in the past 12 months.

Regulatory Loopholes at Retail Prices

Delta-8 THC represented an outcome from years of CBD overproduction mixed with lack of a regulatory framework for the U.S. CBD/hemp-derived cannabinoid industry. It showcased how operators are inclined and enabled to exploit opportunities in the legal gray area lacking specific clarity from regulators. The delta-8 market exploded during 2020, and early 2021 before state-level bans began to restrict and prohibit sales.

The degree of the disconnect was illustrated in September by a public safety warning issued by the FDA.

In 2018 and 2019, farmers across North America, eager to capitalize on the CBD wave, jumped into speculative hemp production without contracts. That proved to be a leading factor behind the current oversupply of CBD hemp biomass.

Furthermore, lack of federal regulatory clarity from the FDA about products containing hemp-derived CBD limited access to mainstream retail distribution channels for brands and manufacturers. In turn, the market for CBD products has not realized the CAGR growth that some had anticipated.

The meteoric rise of delta-8 THC (delta-8) was borne from myriad factors highlighting larger trends across the U.S. cannabis landscape. Delta-8’s molecular similarity to delta-9 THC and the psychoactive compound that legally distinguishes industrial hemp from marijuana under U.S. law made it easy for manufacturers to market the compound as “weed light” to a widening consumer market.

Consumer interest in delta-8 was particularly high in jurisdictions which prohibit access to medical or recreational consumer marijuana. Delta-8 effectively existed in such gray areas due to the regulations of the 2018 Farm Bill, ultimately if incidentally allowing it to be sold through distribution channels as disparate as gas stations and convenience stores.

In March, New Frontier Data reported that the average price of delta-8 THC biomass had fallen 45% since August 2020, with full-year projections for U.S. sales of delta-8 THC exceeding $10 million.

Come 2021, the average per-kilogram price of delta-8 rose 4% in May, to a high of $1,227.15. However, prices subsequently have fallen sharply: In June prices were down 1% to $1,215; by July prices fell by a whopping 12%, to $1,069.20; and by November they dropped to $1,015.74. With a spate of bans enacted during the year, and the FDA’s stern public health warning, the commercial optimism about delta-8 has seemingly fizzled.

Cultivators also lack confidence in the government after the FDA’s rejection of CBD as a New Dietary Ingredient (NDI).

Despite three years having passed since passage of the 2018 Farm Bill, the FDA remains yet to produce a definitive regulatory framework for products containing hemp-derived CBD. Now, it seems regulations are even further out of reach, as the agency has reconfirmed its position that CBD is subject to the drug preclusion language in the federal Food, Drug, and Cosmetic Act, per objection letters posted regarding New Dietary Ingredient Notifications (NDIN) filed by Charlotte’s Web and Irwin Naturals citing a lack of clinical research.

While the FDA did release a Data Acceleration Plan (DAP) in the fall to accumulate data on products containing hemp-derived CBD from “novel” sources like social media, industry stakeholders are growing ever more disillusioned. Overall, signals from the FDA suggest that the industry remains years away from seeing a regulatory framework for the manufacturing and sale of products containing hemp-derived cannabinoids.

The open-ended inaction has a negative impact on continued capital investment and access to mainstream retail distribution channels for manufacturers of hemp-derived CBD products. Facing such, many stakeholders are turning their sights to Congress to pass legislation which would force the FDA to regulate the products. Two bills (one in the House, one in the Senate) seek to federally regulate products containing hemp-derived CBD, H.R. 841  and S. 1698.

The expectation that the industry will regulate itself or provide the funds for clinical research is unrealistic. Given that retail sales of CBD-infused foods, beverages, and supplements saw sharp declines from June 2020 to June 2021, brands will likely prioritize survival, even if that means operating in regulatory gray areas.

According to the wellness-focused data technology firm SPINS, sales of CBD supplements fell 6% in 2020, and sales of CBD beverages fell 11% year over year from April 2020 to April 2021. In May, GT’s Living Foods (a market leader for kombucha) scrapped its plans to release a CBD-infused beverage line, citing regulatory uncertainty.

The post The Year in Review: Pressure Points Against Progress appeared first on New Frontier Data.

from New Frontier Data https://newfrontierdata.com/cannabis-insights/the-year-in-review-pressure-points-against-progress/

source https://ozlemhermsen.tumblr.com/post/670896580693540864

As Europe Adopts Legal Cannabis Reforms, Employment Becomes Jobs Won

By Oliver Bennett, Special Contributor to New Frontier Data

Despite ending another year compromised by the worldwide COVID-19 pandemic, the legal cannabis industry can afford some optimism looking toward 2022. While the pandemic remains an ongoing crisis, with Europe adopting frequently updated restrictions, there are nevertheless positive trends taking shape for the industry in the new year.

Most notably, the three coalition parties forming Germany’s next government appear in agreement to legalize adult-use cannabis.  Pending ratification by the Social Democrats, Greens, and pro-business Free Democrats, the move looms as an international game-changer, as Europe’s most influential and populous nation will set precedents for the agendas of other countries.

While Malta and Luxembourg will technically beat Germany to market, other countries positioned for cannabis reforms include Spain, Portugal, Finland, the Netherlands, and Switzerland.

It is also likely to have a knock-on effect of easing remaining restrictions on medical cannabis. As New Frontier Data detailed over the summer, “with an expected million-plus German patients gaining access to cannabis by 2024 and a medical cannabis market expected to be worth around €7.7 billion by 2028, one can see why Germany is considered a grail. Meanwhile, across Europe, with a population of 748 million and an annual healthcare spend exceeding €2.1 trillion (EUR), the expectation is that the continent will become the largest world market for medical cannabis.” Much of the optimism revolves around mechanisms for economic recovery,  as previously outlined by New Frontier Data.

Of course, to achieve a functional industry, skilled labour will be required. A university survey commissioned by the German Hemp Association posited that legalising cannabis could create some 27,000 jobs while generating new tax revenues of about 3.4 billion euros annually.

Meanwhile, the U.K. Cannabis Industry Council estimated that 100,000 jobs could be created in medical cannabis alone in a report called U.K. Medical Cannabis & CBD Market – Ten Recommendations for Government by Professor Mike Barnes, interviewed here in April. More recently, the drug reform group Volteface reported that the U.K. could be missing out on a potential £1.2 billion medical cannabis industry and 41,000 potential jobs due to outdated licensing regimes.

Elsewhere, the social benefits of job creation amid the pandemic’s disruptions are vital to the case for cannabis reform and investment. Recently, in the U.K. Channel Island of Guernsey, 4C Labs became the first company licenced to grow medical cannabis, partly on the premise that it could create more than 60 jobs – labour that might otherwise emigrate. As Greg Dobbin of 4C Labs said, medical cannabis could start being grown locally from early 2023. “I would say that one of the greatest benefits to Guernsey is… if you can create new opportunities for younger people, you can retain them.”

Similarly confident attitudes prevail in the rest of the UK. In autumn 2021, the Telegraph – a Conservative publication – welcomed that “cannabis could be the new gold rush”. While the U.K. is a world leader in producing medicinal cannabis, it exports it in the absence of a legal market, leaving Britain at risk of being left behind by a growing industry. Compare it to the U.S., where (according to a report from Leafly) the legal cannabis industry employs some 321,000 people – a larger cohort of the workforce than paramedics, airline pilots, or electrical engineers.

Toward providing the labour, Lumino claims to be the first cannabis agency in Europe if others have also staked the space out, including Handpicked Jobs – a cannabis-specific recruitment platform connecting industry pioneers with “exceptional talent… at the dawn of an immense new global cannabis industry.”

Created by entrepreneur George Vincent, Handpicked Jobs hopes to become the “U.K.’s go-to recruitment platform for cannabis-specific jobs,” and claims over 15,000 candidates signing up already – suggesting that the cannabis industry may still be a buyer’s market in terms of recruitment. Other forays into the recruitment sector include Blume (which in 2019 claimed to be Europe’s first “cannabis recruitment agency aligning talent within the legal cannabis industry”), Cannalist’s European cannabis jobs board, and Businesscann, which last month launched a  jobs portal for the European cannabis industry, claiming to be “the ideal destination for businesses looking for new staff… [and to] those looking to join one of the planet’s fastest-growing industries”.

The specifics of the cannabis jobs market make recruitment strategies critical. Sectors where cannabis could draw from include biotech, agritech, IT, marketing, quality control, laboratory technicians, jobs in cultivation, and much more. As the market develops it could also fold in jobs in retail and hospitality – a phenomenon that has already been observed in the U.S., as part of the move from undervalued jobs in retail to more quality-of-life employment – sometimes characterised as ‘the Great Resignation’ – which has seen a boost to the cannabis industry by adding over 77,000 jobs across the sector, spanning minimum-wage positions to six-figure salaries. Young and mobile, workers in the rapidly maturing industry can move up the ladder in a shorter time frame than in more established industries.

In the U.S. there’s also a maturing sector of cannabis courses, with some in established universities as well as among start-ups. Some like the Colorado-based Clover Leaf University, have existed for over a decade; it also offers workshops in another 10 U.S. cities.

In Europe the training and course market is much less developed. Still, the Cannabis Training University, claiming to be ”the world’s leading online cannabis college”, has specialist portals for European countries including Germany and the Netherlands.

Given that the training side is sure to grow, and  a skills shortage remains in the European industry, North Americans are being recruited in the European market over and above local workers. For some, that raises the issue of safeguarding. This brings safeguarding to the fore.

David Cooper of the Economic Policy Institute think tank told The Washington Post that “there is an urgency to establish guardrails now, for well-paying, middle-class jobs before cannabis is legalized federally and really takes off. Otherwise, these jobs could quickly start to look like existing retail and agriculture jobs, which are oftentimes the worst jobs in the economy.” Workers’ rights groups in the established North American cannabis industry are now calling for greater unionization, claiming that it is at a critical time in the industry to establish protections.

As the cannabis industry moves forward into a year full of hope, its foundations should be as solid as possible, so it can attract the talent it sorely needs.

New Frontier Data does not endorse any of the organisations cited in the article.

The post As Europe Adopts Legal Cannabis Reforms, Employment Becomes Jobs Won appeared first on New Frontier Data.

from New Frontier Data https://newfrontierdata.com/cannabis-insights/as-europe-adopts-legal-cannabis-reforms-employment-becomes-jobs-won/

source https://ozlemhermsen.tumblr.com/post/670802218434379776

Can CBD Help Manage the Symptoms of Chlamydia?

What Is Chlamydia?

Chlamydia is a common sexually transmitted infection that is caused by the bacteria Chlamydia trachomatis and that spreads through sexual contact or contact with infected fluids. It can develop in the throat, cervix, rectum or urethra and may or may not present symptoms right away. Even when symptoms of chlamydia do develop, they are typically mild in the beginning and so easily overlooked. Once chlamydia matures into a full-blown infection, the infected may experience the following symptoms:

•         Vaginal discharge

•         Discharge from the penis

•         Painful urination

•         Bleeding after sex and between periods for women

•         Painful intercourse for women

•         Testicular pain

If left untreated, chlamydia can lead to more serious health problems and possibly result in infertility in women.

How CBD Can Help Chlamydia

According to research, CBD is a natural pain reliever, stress reliever and immune defense, making it a viable treatment for STDs and STIs. Diagnosed persons who use CBD for pain management found that it helped to alleviate the burning sensation, reduce the pain in the genitals and reduce inflammation. Moreover, it helped alleviate the stress of living with an STI.

CBD for bacterial infections in general proves to be a promising treatment. According to additional studies, CBD can help to restore damaged cells. This is particularly helpful when dealing with chlamydia, as chlamydia is characterized by extensive tissue damage.

How To Apply CBD Oil for Chlamydia  

Despite the lack of research regarding chlamydia and CBD use, what evidence does exists suggests that CBD oil cannot hurt. Start with a small dosage of CBD oil and massage it gently to the infected area. Do this for up to two minutes. Let it sit to maximize the oil’s restorative properties.

The post Can CBD Help Manage the Symptoms of Chlamydia? appeared first on Smart CBD Hub.

from Smart CBD Hub https://smartcbdhub.com/can-cbd-help-manage-the-symptoms-of-chlamydia/
via IFTTT

source https://ozlemhermsen.tumblr.com/post/670755326393565184

$10B+ in Cannabis Capital Raises to Exceed Pre-Pandemic Levels

New Frontier Data releases investment activity study ahead of potential U.S. federal reform

Washington, D.C., December 15, 2021 — New Frontier Data (https://newfrontierdata.com), the premier data, analytics and technology firm specializing in the cannabis industry worldwide, publishes its latest report, Cultivating Capital: Cannabis Finance & Investment, released in partnership with FTI Consulting, examining emerging trends, opportunities and risks to investment capital as cannabis normalization continues to prevail in the absence of a federally regulated marketplace.

The report found that since 2019, capital raises in the cannabis industry have totaled $25.6 billion, with $10.1 billion in the first three quarters of 2021 alone, reflecting recent investment in product innovation, improved therapeutic applications, and technology-enabled solutions commensurate with a mainstream industry. Consumer demand is a key driver with cannabis consumers spending an estimated $415 billion globally on high-THC cannabis in 2020, and that is projected to grow to nearly $500 billion by 2025.

“North American companies—both Canadian and American—are deploying an unprecedented amount of capital in emerging European and Latin American cannabis markets,” noted Giadha A. DeCarcer, Founder and Executive Chair of New Frontier Data. “These strategic investments are positioned to capture the significant consumer and commercial opportunities now arising across the maturing global cannabis economy.”

Key Findings:

• Federal Prohibition: Increasing market sophistication is enabling cannabis companies to navigate the challenges created by federal prohibition, while cannabis normalization has bolstered investor confidence in federal reform.

• M&A Investment Trends: Investments in cultivation and retail facilities accounted for 60% of 2021 deals (over $6 billion), but investors also bet big on technology companies, with 2021 seeing the largest tech deals to date.
• Global Expansion: As the first G7 country to legalize cannabis, 67 (50%) of Canada’s M&A transactions in 2021 occurred in foreign markets compared to five U.S transactions (5%), validating the synergy between legalization and global expansion.

Download a complimentary copy of Cultivating Capital: Cannabis Finance & Investment, here: https://info.newfrontierdata.com/cultivating-capital

About New Frontier Data:

New Frontier Data is the premier data, analytics, and technology firm specializing in the global cannabis industry, delivering solutions that enable investors, operators, advertisers, brands, researchers, and policymakers to assess, understand, engage and transact with the cannabis industry and its consumers.

Our mission is to inform policy and commercial activity for the global legal cannabis industry. We maintain a neutral position on the merits of cannabis legalization through comprehensive and transparent data analysis and projections that shape industry trends, dynamics, demand and opportunity drivers. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with a presence in Europe, Latin America and Africa. For more information about New Frontier Data, please visit us at www.NewFrontierData.com.

Media Contact: 

Susan Clayton Hammann
Marketing & Communications Director 

New Frontier Data
+1 844-420-3882 ext. 3 

media@NewFrontierData.com 

 

The post $10B+ in Cannabis Capital Raises to Exceed Pre-Pandemic Levels appeared first on New Frontier Data.

from New Frontier Data https://newfrontierdata.com/cannabis-insights/10b-in-cannabis-capital-raises-to-exceed-pre-pandemic-levels/

source https://ozlemhermsen.tumblr.com/post/670704082115264512

How To Use CBD for Parkinson’s Symptoms Including Emotional Changes

Parkinson’s Symptoms in Everyday Life

Though Parkinson’s disease patients are known for the characteristic tremors that may cause shaking hands, difficulty walking, and speech difficulties, they may deal with a host of additional symptoms daily that can include emotional changes ranging from mild to extreme. Mood changes are often a core symptom of this neurological disease. In more advanced cases, Parkinson’s patients may suffer from dementia and hallucinations.

How CBD Can Help Parkinson’s Patients

Progressive, neurological diseases such as Parkinson’s are difficult to manage even with modern medications and therapy. Patients often work with a team of medical professionals to manage movement, sleep, pain, and emotional issues. Depression, in particular, can be a component of Parkinson’s, and it may be an indication that the condition is worsening over time. CBD improves mood issues in many Parkinson’s patients. If you or a loved one has Parkinson’s, you could try using cannabidiol products for the following symptoms:

•         Depression

•         Anxiety

•         Tremors and other motor symptoms

•         Chronic pain

•         Insomnia

•         Psychosis symptoms such as hallucinations

Dementia that accompanies Parkinson’s often results in hallucinations, extreme mood swings and irritability, and depression. Many patients feel that they have lost control of both their movements and their emotional responses to everyday events that would otherwise not upset them. Consider using CBD for stress and better sleep when looking at alternative treatments that help you manage emotional changes related to Parkinson’s disease.

The post How To Use CBD for Parkinson’s Symptoms Including Emotional Changes appeared first on Smart CBD Hub.

from Smart CBD Hub https://smartcbdhub.com/how-to-use-cbd-for-parkinsons-symptoms-including-emotional-changes/
via IFTTT

source https://ozlemhermsen.tumblr.com/post/670570359350837248

Santa Claus Paganism and Psychedelic Mushrooms of Siberia

The tale of Santa Claus and Christmas can be traced back to numerous different origins and cultures throughout history. The most popular narrative is the legend of Saint Nicholas, a Christian bishop of Greek descent who was known for his kindness and generosity. It’s a great story, but it’s not the only historical account of Santa Claus, and personally, it’s not my favorite rendition.  

The reality is that winter festivals and a version of “Christmas” have been celebrated since long before Christianity swept the world, and certain elements of Santa Claus’ life and common Christmas themes seem to better align with ancient Pagan and Shamanic traditions of centuries prior. In this article, we’ll explore the Siberian and Arctic regions, where, as the story goes, ‘Santa’ was actually a local shaman who dropped bags of psychedelic mushrooms into the homes of residents during the winter solstice.  

Christmas stories are fun, espeically when they include psychedelics. Remember to subscribe to The Psychedelics Weekly Newsletter for more articles like this one and all the latest, most exciting industry news. And save big on Delta 8, Delta 9 THC, Delta-10, THCO, THCV, THCP & HHC products by checking out our “Best-of” lists!

---

What is Paganism? 

In the mainstream world, there are a lot of preconceived notions about paganism connecting it to witchcraft and Satanism, but these ideas simply are not rooted in any sort of fact. The word ‘Pagan’ is an umbrella term coming from the Latin word ‘paganus’ which can be roughly translated to mean “those who live in the country”.   

When Christianity began to take hold in the Roman Empire, it happened mainly in larger cities. The new Christian began using the word ‘pagan’ to describe those living in rural areas who continued to follow and believe in the old ways. 

Nowadays, a Pagan is basically anyone who is spiritual but falls out of the realms of major religion, although the definition does still vary a bit depending on who you ask. Christians, Jews, and Muslims use this term to categorize those involved in “any religious act, practice, or ceremony” that is not theirs. Hindus, Buddhists, and others define it as “being without a religion”.  

In a way, these definitions are accurate. Paganism is technically not a religion, but a system of overlapping beliefs lacking an official doctrine or text (like the Bible, Koran, Tanakh, etc.). A common thread among Pagans is a belief in the divine and natural order of the universe.   

Nature’s Medicine Cabinet: Top 6 Non-Psychoactive Healing Plants

Christmas before Christianity  

In modern culture, Christmas is a Christian holiday commemorating the birth of Jesus Christ and celebrated on the 25^th of December. But prior to the birth of Christianity, winter festivals with Christmas-like elements were incredibly popular among European and Siberian Pagans. Some of the Christmas traditions that we still know and love today stem from Celtic winter celebrations, like the hanging of mistletoe and ivy.  

Take the Germanic, midwinter festival known as Yule. It was time for festivities, baking, decorating, gift giving, and family that occurred over a period of 12 nights around the winter solstice (yes, that is where 12 days of Christmas come from). So much of the current iconography and themes that we associate with modern-day Christmas – such as the Yule log, decorated trees, the wreath, holly, mistletoe, and the star – all originated from Yule.  

Other European cultures had their own festivals and celebrations, components of which were stolen by Christian settlers as well. Ancient Romans celebrated Saturnalia, a festival celebrated from December 17^th to 23^rd and celebrated the agricultural god Saturn. During Saturnalia, people would also decorate their homes with intricate wreaths and different types of greenery.  

Even Christmas carols come from the ‘Kondela’, an Eastern European, pagan custom of singing seasonal songs to drive away evil. These kondelas were sung during their winter festivities to protect the villages and usher in a blessed new year. 

Merry Cannabis! Christmas and Marijuana

Santa the Siberian Mushroom Shaman 

Some of our Christmas customs even come from further east, from the Evenki Northern Tungusic people in what is currently known as Siberia. The Evenki were hunter-gatherers and reindeer herders, and their survival depended almost entirely on the latter. Reindeer provided the tribes with almost all their basic needs including food, transportation, milk, clothing, tools made from the bones and antlers, as well as cultural, spiritual, and artistic inspiration and customs.  

The Evenki participated in a form of Paganism, known as Shamanism. The word “shaman” can be traced back to the Tungus word “saman”, which can be loosely defined as “one to talks to spirits”. A prominent aspect in their Shamanic rituals included the consumption of Amanita muscaria, or the Fly Agaric Mushroom. This fungus, arguably the most recognizable species of toadstool mushrooms, is known for its powerful psychoactive effects, attributable to the presence of the neurotoxins ibotenic acid and muscimol. 

Amanita muscaria was sacred to the indigenous people of Siberia and the Evenki Shaman used them regularly during ceremonies and rituals. Because these mushrooms can be very toxic, they need to dry a bit before eating. While collecting the mushrooms, people would lay them out under the big evergreen trees in the woods, very much resembling a present-day Christmas tree with red and white bulbous ornaments.  

Amanita muscaria (fly agaric mushrooms)

“Why do people bring pine trees into their houses at the Winter Solstice, placing brightly colored (red and white) packages under their boughs, as gifts to show their love for each other?” asks James Arthur, author of Mushrooms and Mankind. “It is because, underneath the pine bough is the exact location where one would find this ‘Most Sacred’ substance, the Amanita muscaria, in the wild.” 

Once ready, the shaman would collect all the mushrooms in a large sac and deliver them to the villagers as gifts during the winter solstice. The villagers would then continue the process of drying their mushrooms by handing them in a sock near the fire. Sounds vaguely familiar right? It’s because the Santa we tell our children about today is just a modern counterpart of an ancient shaman who consumed psychedelic plants to connect with the natural and spiritual world.  

Magical Reindeer, Chimney Drops, and other stories 

 Again, reindeer play a pivotal role of the Tungusic people’s existence and success. According to Mircea Eliade, “shamans take on a chimeric association with regional animals including wolves, bears, fish, and reindeer. The shaman dies to his old identity as he assumes this hybrid role, where the animal symbolizes a real and direct connection with the beyond.” 

In Siberia, it’s not uncommon for reindeer to eat the Amanita mushrooms, and yes, they do feel the psychotropic effects to some extent, although how ‘high’ they actually get still remains up for debate. Some experts theorize that, while humans seek out psychedelics to feel of sensation of spiritual connection, some animals might use them to make the monotony of a cold, bleak, depressing winter a bit more tolerable.  

The chimney symbology hails from these pagan, shamanistic Siberian communities as well. We know that shamans were collecting magic mushrooms and delivering them to the homes of their people, but how they entered the homes is another story. Since it was common to be snowed in during that time of the year, the teepee-like homes had an opening in the roof, to allow smoke from fireplaces to escape and for people to enter and exit when there was too much snow. And so the Santa chimney story was born.  

Speaking of mushrooms and gift giving, this story is not unique to Siberian shamans, as surprising as that sounds. The Sami Shamans of Lapland in Northern Finland share similar tales of winter parties, passing out healing fits to children, and drying psychedelic mushrooms and trees.  

 “An all-knowing man who defies space and time? Flying reindeer? Reindeer-drawn sleds? Climbing down the chimney? The giving of gifts? The tales of the Sami shamans have it all,” says Matthew Salton director/producer of New York Times Op-Docs Santa is a Psychedelic Mushroom.  

“Regional connections shouldn’t surprise us. Wherever psychedelics appear in nature, rituals have emerged to celebrate them. Secret societies being built around the notion of death and resurrection are a repeated historical phenomenon. And what story better fits the mythos of Santa Claus, a man dressed like a psychedelic mushroom who is reborn every year, flying around the world bringing healing gifts to children, yet is never seen by a soul?” 

Good Trip Guaranteed: Common Mistakes To Avoid When Using Psychedelics

Conclusion 

Almost every single contemporary Christmas tradition can be traced back to paganism, and the same can be said for Easter and Halloween. When the first Christian missionaries were forcibly converting the people of Europe, they found it easier and less controversial to simply repackage the annual festivities as “Christian Holidays” and just let people continue celebrating as they had been. 

But just because we have been fed a certain story our whole lives, that doesn’t necessarily mean that it’s the ultimate truth. As a matter of fact, most of what we know about holidays, religion, and history is inaccurate and we’re learning more every day about the importance to due diligence and doing your own research.  

When you get down to the core of it, the idea of Santa being a mushroom-eating shaman who rode an intoxicated reindeer to deliver gifts to local children on the winter solstice, oddly, makes more sense than the alternative.  

Hello readers! Thanks for joining us at CBDtesters.co, the #1 internet location for the most recent and interesting cannabis and psychedelics-related news from around the globe. Visit the site everyday to stay abreast of the quickly-moving landscape of legal drugs and industrial hemp, and sign up for The Psychedelics Weekly Newsletter, to ensure you always know what’s going on.

Disclaimer: Hi, I’m a researcher and writer. I’m not a doctor, lawyer, or businessperson. All information in my articles is sourced and referenced, and all opinions stated are mine. I am not giving anyone advise, and though I am more than happy to discuss topics, should someone have a further question or concern, they should seek guidance from a relevant professional.

The Psychedelics Weekly Newsletter

The post Santa Claus, Paganism, and Psychedelic Mushrooms of Siberia  appeared first on CBD Testers.

Via https://cbdtesters.co/2021/12/14/santa-claus-paganism-and-psychedelic-mushrooms-of-siberia/

source https://rosalinaklerkx.weebly.com/blog/santa-claus-paganism-and-psychedelic-mushrooms-of-siberia

source https://rosalinaklerkx.tumblr.com/post/670549461313929216

source https://ozlemhermsen.tumblr.com/post/670549507766878208

Among Key Trends in ’21: Increasing Use of Debt and Rising Deal Sizes

By Kacey Morrissey, Senior Director, Industry Analytics

According to New Frontier Data’s latest modeling, cannabis consumers in 2020 globally spent an estimated $25 billion in legal markets, but total demand in both legal and illicit markets was closer to $400 billion. The wide gulf between the current legal market and the 20x larger total addressable market illustrates the growth potential as more countries establish regulated markets. While much of the industry’s operational and capital activity in has focused on the North American markets, the growing list of countries softening their position on cannabis has affirmed the mid- and long-term growth opportunities for companies establishing themselves in legal regulated markets.

New Frontier Data’s latest report, Cultivating Capital: Cannabis Finance & Investment, provides in-depth analysis of emerging trends in cannabis finance and investment, and anticipates key challenges and opportunities during a period of phenomenal growth. On Thursday (Dec. 16) at 3 p.m. EST, a webinar titled Cannabis Capital: Trends in 2021 and Opportunities Ahead, features experts from FTI Consulting joining New Frontier Data experts in reflecting on topics including: private capital limitations and industry operationalization; industry fragmentation and deal flow; intellectual property as a competitive differentiator; and strategic positioning for global expansion, among other subjects. Register here for the free event.

The industry’s strong tailwinds have driven unprecedented capital flow into the industry as investors fund the next stage of industry growth. The first half of 2021 saw a spate of record cannabis deals in virtually every industry sector, companies raced to enter new markets, expand operational capacities, and acquire novel intellectual property in the wake of the rapidly growing industry.

The use of debt as a source of funding has increased steadily in recent years, as equity markets have shown their limitations and debt has been considerably cheaper than in recent years, specifically for the largest and best-performing companies. An advantage of the method is that — unlike equity financing — debt financing affords complete control to the business owner, who is not obligated to answer to investors. Tax deductions – unlike private loans, interest fees and charges on a business loan are tax-deductible.

While debt accounted for 18% of capital raises in 2018, debt’s share rose to nearly 40% YTD ’21, and average debt raises more than doubled to an average of $47.4 million per deal, up from $20.2 million in 2018.

The year 2021 marked the first that any major listed U.S. cannabis company secured a debt deal at with coupons below 10% – the U.S. cannabis multistate operators (MSOs) Green Thumb Industries secured a three-year loan at 7.1% (9.1% after factoring warrants), and Trulieve Cannabis Corp. managed a $350 million raise by issuing a five-year secured bond callable after two years with an 8% coupon.

In general, larger MSOs are enjoying lower interest rates on debt this year because of stronger balance sheets, improved liquidity, and expectations that federal cannabis reforms (either with decriminalization or more incremental changes to address banking and taxation issues) will catalyze overnight profitability and explosive growth for the best-resourced companies.

Dutchie, a technology company that powers e-commerce and point-of-sale solutions for cannabis retailers, is among a growing list of companies raising large rounds in 2021. The company’s $350 million Series D in October was the largest of the year to date, and follows its $200 million round from March (Dutchie having raised $603 million to date).

Jane Technologies, another retail sales technology platform, raised a $100 million Series C in August while Kadenwood, a CBD consumer products company, closed a $50 million Series B. Other companies turning to post-IPO equity include MedMen, the multistate operator, which raised $100 million from a private placement investment. Meantime, Weedmaps, the storied B2C retail platform, drew a $325 million investment alongside its SPAC.

The post Among Key Trends in ’21: Increasing Use of Debt and Rising Deal Sizes appeared first on New Frontier Data.

from New Frontier Data https://newfrontierdata.com/cannabis-insights/among-key-trends-in-21-increasing-use-of-debt-and-rising-deal-sizes/

source https://ozlemhermsen.tumblr.com/post/670522852567613440

Its Official Indiana Will NOT Legalize Cannabis Until Federal Govt. Does

As many already anticipated, anti-cannabis Governor Holcomb of Indiana made a recent announcement stating that he will NOT consider medical marijuana, decriminalization, or any type of regulatory infrastructure until cannabis is federally legal; but that he’s ‘open’ to allowing regulated sales once prohibition ends.  

Cannabis laws are complicated and often unjust, but that’s something we in the industry are used to dealing with. What gets difficult is keeping up with the ever-changing landscape of legal cannabis. For more articles like this one, and for exclusive deals on flowers, vapes, edibles, and other products, make sure to subscribe to The THC Weekly Newsletter. Also save big on Delta 8, Delta 9 THC, Delta-10 THC, THCO, THCV, THCP & HHC products by checking out our “Best-of” lists!

---

Cannabis in the Hoosier State 

When it comes to personal views vs state laws, Indiana is in stark juxtaposition. Speaking anecdotally, everyone I have ever met in Indiana either uses cannabis products, or doesn’t but still supports legalization and personal choice. And I have lived here off and on for about 4 years now, so I’ve spoken to quite a few different people on the matter.  

Statistically, the numbers are not far off from what I’ve been noticing. Regional surveys have found that 84% of Hoosiers support more lenient and progressive cannabis regulations. Approximately 39 percent of Hoosiers favor allowing cannabis to be used for any purpose, while 42 percent prefer medical use only to be permitted. Regardless, only 16 percent of Indiana residents support the laws as they currently stand, so suffice it say, there is a huge discrepancy between what the people want, and what Eric Holcomb is willing to give us; at least for the time being. 

Penalties for possession are rather harsh, in Indiana, among the most restrictive in the entire country. A first offense of possession up to 30 grams is a class B misdemeanor punishable by a fine of up to $1000 and up to 180 days in jail. If you have priors, you’re looking at class A misdemeanors and even felony charges. Same goes for subsequent possession charges. If you’re found to be growing and/or distributing, you’re looking at felony for your first offense.  

Understanding The Confusing Cannabis Situation in Indiana

Governor Holcomb’s Statements  

During a year-end interview with Indy Politics conducted earlier this week, Holcomb was asked what he thought about lawmakers starting the process of setting up some type of licensing and retail structure so when cannabis does become legal, Indiana will be ready to launch their own program. “I don’t mind that at all,” the governor replied. 

It’s much different than what other “legal” states have been doing thus far, and the approach is not without benefits. Instead of rushing head first into legalization with no regulatory framework in place, then scrambling to deal with issues at the last minute as they come up, Indiana can look at other states for guidance to creating their own plan with as little room for error as possible.  

Although Holcomb is on board with getting a game plan in place for the future, he made sure to emphasize that cannabis legalization is not a top priority for him, and that no circumstances will sway him to act on this matter before the federal government does.  

“We’re talking about something that is illegal, and it’s just at the core of me—I’ve said this, I’ve taken a couple blows—it’s to uphold and defend the laws of the state and nation,” the governor said. “I don’t get to pick and choose. Even if I agreed with it, I couldn’t get myself to just look the other way as a lot of states have. But just because a lot of other states have doesn’t mean it’s the right thing.”

In the meantime, Holcomb said he does want to see more research into cannabis. “I would encourage research, proper research, to be conducted,” he added. “We’ve got Indiana University and Purdue University that agree to participate in—an ag school, a medical school—to do the proper research as they would with any other controlled substance and get the [Food and Drug Administration] involved in and get real data.” 

American Stoner – Comparing Cannabis Culture in Legal vs Prohibited States

Legal weed on all sides 

Indiana is the last prohibition stronghold in a sea of midwestern green. Looking west, Illinois has a recreational cannabis program that went into effect on January 1^st, 2020. They have a thriving market that has already outpaced liquor sales, totaling around $560 million in the last couple years. There are dispensaries all over the state, even in rural areas.  

Then we go up north to Michigan, where medical cannabis passed back in 2008 and recreational was legalized a decade later in 2018. As of April 2021, the state had a total of 410 medical dispensaries, 260 recreational stores, and 91 pending licenses for new storefronts. They are evenly distributed throughout the state and quite a few are conveniently close to the Indiana state line.  

Other surrounding states are a bit slow to hit the button on full legalization, but the cannabis conversation is ongoing everywhere in the Midwest. Ohio, for instance, has a comprehensive medical program with over 10,000 active patients. To the south, Kentucky has a medical bill in the works that is expected to pass soon. And even further west, both Kansas and Missouri have cannabis-related initiatives waiting to be voted on when sessions reconvene in 2022; recreational in Missouri and medical in Kansas.  

Cannabis Laws in the USA: Which State Is the Most Progressive?

Eli Lily and the pharmaceutical industry roadblock  

Many locals believe that Indiana is basically bought and paid for by Eli Lilly Pharmaceuticals, a known enemy of cannabis reform who has spent hundreds of thousands of dollars lobbying against legalization. Eli Lily is the 4th largest company and employer in the state, with a total of 10,281 employees in Indiana alone – a third of their global worker count. Eli Lily is one of the many pharmaceutical companies that are spending millions every year to lobby against cannabis legalization.  

Knowing what we know about cannabis and how its compounds work with the human endocannabinoid system, it makes sense why it can be used medicinally to treat so many different and wildly varying ailments. It’s also safe to assume that as an effective, non-toxic, and natural therapeutic, cannabis has the potential of completely replacing dozens, if not hundreds, of existing pharmaceutical medications. According to retired police officer-turned-legalization advocate Howard Wooldridge, “Big Pharma is a top opponent of legalization, due to the emerging potential of marijuana as an alternative to Advil, ibuprofen all the way to Vicodin, pills for nausea – I mean expensive store-bought pills.”  

This theory is further cemented by a recent study claiming that, on average, states providing easy access to medical marijuana saw a 20 percent drop in prescription drug use, particularly opioids. A review of 79 total studies on this subject found that patients experienced, roughly, a 30 percent improvement in pain with cannabinoids compared to placebos, and in states where dispensaries are widely distributed, the rate of opioid-related hospital admissions and deaths dropped by 15-35 percent. 

A lot of the main figures in the fight against cannabis legalization are the companies making opioid painkillers such as Oxycontin and Zohydrol. “It’s more than a little odd that groups leading the fight against relaxing marijuana laws derive a significant portion of their budget from opioid manufacturers and other pharmaceutical companies.” – Lee Fang, Journalist and Investigative Reporter at The Intercept. But it’s not just pain medication that takes a back seat to the powers of medicinal cannabinoid, in legal states, doctors report writing fewer prescriptions for depression, anxiety, seizures, and nausea medications as well.  

Any unbiased comparison of benefits vs risks would find that weed is superior to prescription pills on a regular basis. No matter how you look at it, the financial stakes are crazy high. In addition to big pharma obviously trying to protect its $10 billion annual revenues, prescription pill dependency causes a ripple effect of additional problems, many of which are expensive and profitable. For example, think of all the incurred medical and rehabilitative treatments needed to treat opioid addiction, repeated overdoses, and spread of disease within drug-using communities.  

The more pills you’re one, the more money they make… and more cannabis you have access to, the less pills you need to take. It’s pretty easy to see the conflict here.  

Money Talks: Political Lobbying Against Cannabis Legalization, What You Need to Know

Conclusion  

This is Indiana, so we can’t expect too much. But it’s good to know that once possession of cannabis is federally legal, Governor Holcomb won’t hinder the state’s ability to implement a recreational market, which will translate to a lot of revenue for the state. So far, Rep. Sue Errington (D) from Muncie has been assigned to the case, and she claims to be working on a bill “along the lines of what the governor says he’s open to”. She recently hosted a town hall event to get more opinions from constituents.  

My personal concern is that Indiana will remain one of the more restrictive states even post legalization (regarding personal cultivation laws, sale of concentrates, zoning limitations, etc.), but anything is a step in the right direction at this point. 

Hello and welcome! You made it to CBDtesters.co, your one-stop-shop for the most up-to-date and thought-provoking cannabis and psychedelics-related news, offering up the most relevant stories of today. Join us frequently to stay informed on the quickly-moving universe of legal drugs and industrial hemp, and sign up for The THC Weekly Newsletter, to make sure you always know what’s going on first.

Disclaimer: Hi, I’m a researcher and writer. I’m not a doctor, lawyer, or businessperson. All information in my articles is sourced and referenced, and all opinions stated are mine. I am not giving anyone advise, and though I am more than happy to discuss topics, should someone have a further question or concern, they should seek guidance from a relevant professional.

The DELTA 8 Weekly Newsletter

The post It’s Official, Indiana Will NOT Legalize Cannabis Until Federal Govt. Does  appeared first on CBD Testers.

Via https://cbdtesters.co/2021/12/13/its-official-indiana-will-not-legalize-cannabis-until-federal-govt-does/

source https://rosalinaklerkx.weebly.com/blog/its-official-indiana-will-not-legalize-cannabis-until-federal-govt-does

source https://rosalinaklerkx.tumblr.com/post/670462667202396161

source https://ozlemhermsen.tumblr.com/post/670462674827640832

New Mexican Supreme Court Ruling & the Start of a Commercial Cannabis Market

The Mexican government might be dragging its feet, but the court system isn’t. A new Mexican Supreme Court ruling has now signaled the start of a commercial cannabis market in the country by way of a low-THC industry, done through a ruling in favor of the company Xebra Brands.

The Mexican commercial cannabis market has been waiting to commence for nearly three years. Now, a new Supreme Court ruling is getting it on its way. Luckily, cannabis markets are already set up in 18 states of the US, with tons of products, both regulated and unregulated, to take advantage of. Like the new cannabinoid market which boasts a host of compounds from delta-8 THC to HHC to THCV. It’s the time of year again to think of Christmas trees and stocking stuffers, so check out our deals on cannabis compounds to get the holidays going right.

---

A little background on the Mexican cannabis conundrum

At the end of 2018, a fifth consecutive Supreme Court ruling was made in Mexico related to the recreational use of cannabis. As all five consecutive rulings were somehow in favor of recreational use, this set off something called jurisprudencia. Jurisprudencia happens when five consecutive rulings override stated legislative law, to make new legal precedent. In this case, it was decided that the stated laws of cannabis prohibition were unconstitutional.

When this happened in 2018, the Supreme Court essentially commanded the government to come up with new legislation that was in concert with these court rulings, which had just become law by way of jurisprudencia. Otherwise, the written laws, and the new stated laws would be in contrast, with one set saying prohibition is unconstitutional, and one set saying that the cops can arrest a person for possession and use.

This was all fine and good, except the government has been wriggling out if its responsibility since it was given it. At the first deadline, one year after the rulings, the government could not pass a bill, and asked for an extension by the court, which was granted. Deadline two came in spring of 2020, at which point the government asked for and received, once again, an extension. Third deadline came in December of 2020, and for the third time, an extension was asked for and granted. This brought us to April 2020, when not only did the government not have the work done, but it didn’t even ask for an extension.

By not asking for an extension, it was sort of like the government flipping the bird to the Supreme Court. But apart from being a rude gesture (or showing of incompetence), it also kicked it back to the Supreme Court to do something to maintain its ruling. So, on June 28^th 2021, the Supreme Court – without a bill passed to institute laws or a regulated industry, dropped the laws of prohibition around personal cultivation and use making Mexico the 4^th legalized country. Nothing else changed though. At least, not until the Supreme Court was forced to make a new decision.

Supreme Court ruling opens Mexican commercial cannabis market

The initial ruling in 2018 did nothing to establish a Mexican commercial cannabis market; such structures generally come from written legislation. Even the dropping of the laws of prohibition this past June also did nothing to institute a commercial market. So now, two years after the first deadline, no law exists, and no market has been created, even though private cultivation and use have been legalized for adults.

A lot can be wagered as to the reason for this delay. According to the government itself, it has to do with infighting over issues like protections for local farmers, and restrictions of use. To those less trusting of government lines, it appears to have more to do with going up against cartels, or making decisions that could put politicians at odds with different illegal organizations.

Mexican Cannabis Legalization: Why Hasn’t Legislation Passed?

Considering over 100 politicians were killed in the lead-up to the 2018 elections in Mexico, it’s hardly far out there to assume individual politicians are afraid to anger the very organizations which have already been running these black-market industries for decades. This is what I think, but you can form your own opinion on the situation.

Anyway, though the government continues to stall, the Supreme Court has once again pushed forward in favor of its own ruling, making yet another ruling in a different case, which starts the process of opening a Mexican commercial cannabis market. The ruling, made on December 1^st, was in favor of the company Xebra Brands, whose Mexican subsidiary Xebra Mexico, went to the Supreme Court over what it said was the unconstitutionality of not allowing cannabis to be grown commercially with 1% THC or less. Xebra Brands can be found on the Canadian Securities Exchange as XBRA.

The case

On December 1^st of this year, the Supreme Court ruled in an unappealable ruling, that it was indeed unconstitutional to bar the production of low-THC cannabis. This ruling now means that Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS) – its national health agency, must implement this decision.

COFEPRIS was challenged in court by Xebra Mexico, over the legality of production for medical and scientific purposes, but not for commercial use. Technically, Mexico is supposed to be instituting such a system – complete with regulation, but since the government hasn’t turned in its homework, the stated laws have remained that commercial cannabis cultivation is illegal. Xebra used the five consecutive rulings, and the announcement of cannabis laws being unconstitutional, to go after COFEPRIS’ ban on commercial production.

It’s not shocking that Xebra won. The Supreme Court has to keep in line with its own ruling, and its own ruling stipulates this should be okay. That there are no laws to govern such an industry is a failing of the government, but shouldn’t erode the peoples’ ability to use  the laws afforded them. And that’s what Xebra did by going up against COFEPRIS in court.

The company now plans to put out a line of low-THC products involving CBD and CBG, in the form of topicals, tinctures, oils and beverages. As can probably be imagined, this should open a floodgate of companies following suit, which should put that much more pressure on the legislature to get its act together if it doesn’t want pandemonium. Or, more realistically, if it wants to be able to tax the industry. That, of course, will mean making real decisions, which the legislature is going to have to buckle down and do.

Mexico Became the 4th Legalized Country

The future of the Mexican commercial cannabis market

If you’ll notice, I didn’t say ‘Mexican regulated commercial cannabis market’, though that’s what it should be. Usually, laws are put on paper to establish rules and oversite for an industry, which include the government’s own cut of it through taxes. Without having laws on the books, not only is there nothing to guide the industry in terms of safety measures, operating guidelines, or industry restrictions and consequences, but it also means the government gets nothing out of it, which governments don’t tend to like.

While it technically could continue this way, it leaves the door wide open for all kinds of abuses. Allowing for abuses within an industry can result in more than simply faulty or fraudulent products, it can lead to real harm and death, and the subjugation of populations. Think of what diamonds did to the people of Africa. Without any form of regulation, no company is beholden to anyone about business practices, and what is used in products never has to be disclosed, or can be lied about profusely. Now think of vape deaths from added chemicals, and how easily that could have been avoided by simply not using the additives that made people sick.

When Mexico’s legislature gets it together, it will provide the laws to regulate the industry, which should then be expanded to include a high-THC market as well. Though Xebra just won the right to produce products, it should be remembered that buying and selling those products still remain illegal.

Xebra will have to do more to get products to market, though perhaps the company is banking on the government doing its job by that time. As of right now, Xebra has no cannabis industry guidelines to go by, and can do what it wants on many fronts. In the future, Xebra will be held to certain requirements, but as of right now, those requirements don’t exist, at least not for cannabis production. In fact, it has not been made clear what government agency will oversee such production, and what preexisting laws related to farming and product production, might apply. Some laws undoubtedly will.

Perhaps Xebra intends to export all products out of the country to be sold elsewhere, or maybe it’ll be waging a new lawsuit to gain the ability to sell in Mexico. Either way, commercial production of low-THC cannabis products is now a thing in Mexico.

Conclusion

With this Supreme Court decision which begins to establish a Mexican commercial cannabis market, Mexico is plunged even more deeply into confusion and disarray. Hopefully this new ruling will light a fire under the collective butt of Mexican Congress, and get it to do its job. If it doesn’t, a new free-for-all is likely to surface and become incredibly intense, and what that will ultimately lead to? Who knows…

Will Mexico Become Biggest Legal Cannabis Market?

Welcome all! Thanks for stopping by CBDtesters.co, your #1 location to catch up on all the most relevant cannabis and psychedelics-related news of today. Drop over for a visit daily to stay informed on the constantly-changing world of legal drugs and industrial hemp, and sign up for The Delta 8 Weekly Newsletter, to ensure you get every news story first.

Disclaimer: Hi, I’m a researcher and writer. I’m not a doctor, lawyer, or businessperson. All information in my articles is sourced and referenced, and all opinions stated are mine. I am not giving anyone advise, and though I am more than happy to discuss topics, should someone have a further question or concern, they should seek guidance from a relevant professional.

The post New Mexican Supreme Court Ruling & the Start of a Commercial Cannabis Market appeared first on CBD Testers.

Via https://cbdtesters.co/2021/12/13/new-mexican-supreme-court-ruling-the-start-of-a-commercial-cannabis-market/

source https://rosalinaklerkx.weebly.com/blog/new-mexican-supreme-court-ruling-the-start-of-a-commercial-cannabis-market

source https://rosalinaklerkx.tumblr.com/post/670462665972449280

source https://ozlemhermsen.tumblr.com/post/670462673837785088